Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 305

Results For "ED"

7875 News Found

Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
News | November 10, 2024

Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr

Q2 FY25 Total Income was at Rs. 85.4 crore


Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr
News | November 10, 2024

Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr

Hospital business revenues increase 13.9% to Rs. 1,655 crore


DuPont launches Tyvek to support sustainable healthcare packaging
Packaging | November 09, 2024

DuPont launches Tyvek to support sustainable healthcare packaging

Tyvek with Renewable Attribution is designed to help reduce the carbon footprint


Lupin receives tentative approval from USFDA for Raltegravir Tablets
Drug Approval | November 09, 2024

Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India


Abbott India reports Q2 FY25 standalone PAT at Rs. 358.61 Cr
News | November 08, 2024

Abbott India reports Q2 FY25 standalone PAT at Rs. 358.61 Cr

The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


Mitsui Chemicals begins sale of i-TFC luminous II dental material range
News | November 07, 2024

Mitsui Chemicals begins sale of i-TFC luminous II dental material range

The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range


Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
Diagnostic Center | November 07, 2024

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM


Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
News | November 07, 2024

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres


RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
News | November 07, 2024

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25